Despite major advances in targeted therapies, immunotherapies, and combination regimens, therapy resistance remains a central barrier to durable cancer ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in RedChip’s upcoming ...
The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized oncology. However, a significant proportion of patients ...
As the “Method of the Year 2024”, spatial proteomics (SP) enables in situ characterization of protein localization, abundance ...
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal cancer.
Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results for a first-of-its-kind investigational therapy applied to the skin and des ...
Ferrocene-modified covalent organic frameworks combine sonodynamic therapy with immune activation to suppress primary breast ...
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...
Determining the presence of a protein in non-tumour cells within the cancer microenvironment could be one of the keys to ...
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to ...
At present, only around 5% of patients with colon cancer are candidates for immunotherapy. This new biomarker could make it possible to determine more accurately which individuals may receive this ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results